This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-23 and is reviewed periodically as new material appears.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Often, as a last resort, if other treatments have failed, the most common procedure is prosthetic implants which involves the insertion of artificial rods into the penis. Some sources show that vascular reconstructive surgeries are viable options for some people.
== Statement on the Generic Masculine in the German Language (2022) == In 2022 in the weekly newspaper Die Zeit, Kermani presented his view on the use of the generic masculine from a writer’s perspective. In this essay, Kermani notes that German is the only language “from which the gender-neutral use of masculine nouns and pronouns could disappear entirely.” He deeply regrets this possible development. After all, the generic masculine “allows for a great deal of linguistic differentiation,” whereas its abolition would promote the sexualization of language and “would not advance gender equality one bit.” As an example, Kermani mentions that German female authors who did not wish to explicitly emphasize their gender still naturally referred to themselves as “Autoren” as recently as the 1970s. But now, the generic masculine is on the decline and is often no longer understood: “No matter how often a linguist may point out that a word like ‘reader’ (‘Leser’)is a generic term and that, strictly speaking, one should say ‘male readers’ when referring exclusively to men—as soon as no one hears female readers implied in the word ‘reader’ anymore, the scholar is, at best, correct only from a historical linguistic perspective.” – Navid Kermani: Mann, Frau, völlig egal [Man, Woman, It Doesn’t Matter at All] According to Kermani, the unique stylistic achievement of the generic masculine is that it does a good job of doing justice to “the diverse transitions, overlaps, and ambivalences” that define what it means to be human.
== Background == Chlorobactene is a monocyclic accessory pigment used by green sulfur bacteria to capture electrons from wavelengths in the visible light spectrum. Green sulfur bacteria (GSB) live in anaerobic and sulfidic (euxinic) zones in the presence of light, so they are found most often in meromictic lakes and ponds, sediments, and certain regions of the Black Sea. The enzyme CrtU converts γ-carotene into chlorobactene by shifting the C17 methyl group from the C1 site to the C2 site.
Cold fusion researchers (McKubre since 1994, ENEA in 2011) have speculated that a cell that is loaded with a deuterium/palladium ratio lower than 100% (or 1:1) will not produce excess heat. Since most of the negative replications from 1989 to 1990 did not report their ratios, this has been proposed as an explanation for failed reproducibility. This loading ratio is hard to obtain, and some batches of palladium never reach it because the pressure causes cracks in the palladium, allowing the deuterium to escape. Fleischmann and Pons never disclosed the deuterium/palladium ratio achieved in their cells; as of 2002 there were no longer any batches of the palladium used by Fleischmann and Pons because the supplier changed the manufacturing process, and researchers still had problems finding batches of palladium that achieved heat production reliably.
=== Distributor's losses and impact === Though Darbar became the highest-grossing Tamil film of 2020, grossing ₹202–250, several distributors claimed that they incurred significant financial losses due to the film’s high acquisition costs and pre-release rights pricing. Trade analysts estimated that distributors collectively suffered losses of around ₹70 crore. It did not perform well in other Indian states, including Andhra Pradesh and Telangana, due to competition from Ala Vaikunthapurramuloo and Sarileru Neekevvaru, and the Hindi version was unsuccessful at the box office due to a lack of promotion. Following unsuccessful discussions with Lyca Productions, a group of distributors attempted to approach Rajinikanth seeking financial relief. Media reports stated that some distributors threatened protests, including hunger strikes, if their concerns were not addressed. Industry commentators later compared the situation to earlier Rajinikanth films such as Baba (2002), Kuselan (2008) and Lingaa (2014). Trade publications attributed the dispute primarily to the film’s high production and acquisition costs. Reports indicated that Rajinikanth and director A. R. Murugadoss received substantial remuneration, contributing to an increased production budget, while the film’s distribution rights were sold at premium rates. Some commentators cited the episode as part of a broader industry debate on the financial risks associated with high-budget star-driven films.
Sources: en.wikipedia.org
== Veterinary medicine == HbA1c testing has not been found useful in the monitoring during the treatment of cats and dogs with diabetes, and is not generally used; monitoring of fructosamine levels is favoured instead.
== External links == Fragmentation patterns in the mass spectra of organic compounds A tutorial in small molecule identification via electrospray ionization-mass spectrometry: The practical art of structural elucidation
== History == Guselkumab was developed by Janssen Pharmaceuticals. In November 2016, Janssen submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking approval of guselkumab.
== Scientific implications and other uses == SPINA-Beta significantly correlates with biomarkers for the allostatic load. The direction is positive, i. e., higher allostatic load is associated with higher beta cell function. This is probably due to increased beta cell mass as a result of dynamical compensation. Together with the reconstructed insulin receptor gain (SPINA-GR), SPINA-GBeta provides the foundation for the definition of a fasting based disposition index of insulin-glucose homeostasis (SPINA-DI). In combination with SPINA-GR and whole-exome sequencing, calculating SPINA-GBeta helped to identify a new form of monogenetic diabetes (MODY) that is characterised by primary insulin resistance and results from a missense variant of the type 2 ryanodine receptor (RyR2) gene (p.N2291D).
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.